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A STUDY OF THE  EFFECT OF INTRAVENOUS LORNOXICAM ON THE 
HAEMODYNAMIC 
RESPONSE FOLLOWING LARYNGOSCOPY AND 
INTUBATION. 
 
The present study was designed as a single-blind randomized controlled trial to 
investigate the effect of lornoxicam on the changes in blood pressure and heart 
rate (HR) observed during laryngoscopy and tracheal intubation in 50 ASA I & 
II patients.  They were divided into two groups of 25 each, one being the study 
group receiving 16 mg iv lornoxicam and the other the control group receiving 
iv placebo.  Heart rate and blood pressure were recorded at various intervals 
during laryngoscopy and endotracheal intubation.  It was observed that there 
was a statistically significant attenuation in heart rate and blood pressure 
response to laryngoscopy and intubation for the lornoxicam group.  Hence we 
can conclude that iv lornoxicam 16 mg 30 minutes before surgery is a simple 
and practical method for the attenuation of the stress response to laryngoscopy 
and endotracheal intubation. 
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                              INTRODUCTION  
 
   Laryngoscopy and intubation are associated with a transient 
cardiovascular stress response characterized by hypertension, tachycardia, 
arrhythmias and increased  circulating catecholamines.  This was known, as 
early as 1951.  This is of little consequence in most of the patients, but 
increases mortality and  morbidity  in patients with coronary arterial 
disease, systemic hypertension, pre eclampsia, increased intra ocular 
pressure and cerebrovascular pathologies such as aneurysms, tumors or 
elevated intracranial pressure.  
 
 Various  techniques  have been proposed to attenuate or prevent   the 
stress   responses following laryngoscopy and tracheal intubation, such as 
omitting Anticholinergic premedication, increasing the depth of  
anaesthesia,  pretreatment with vasodilators such as NTG, opioids, beta 
antagonists  and calcium channel blockers .  The recent studies aiming at 
attenuating or controlling   the   haemodynamic stress response to 
laryngoscopy and intubation focused on the effect of  lornoxicam  with  
different doses. 
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                            AIM OF STUDY 
 
 To determine the hemodynamic effects of IV Lornoxicam during 
laryngoscopy and endotracheal intubation. 
 To determine whether IV lornoxicam is effective in attenuating the 
hemodynamic stress response to laryngoscopy and endotracheal 
intubation.  
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REVIEW OF LITERATURE 
 
           Brace and Reid first described hemodynamic response to 
laryngoscopy   and   intubation as early as 1940.  King et al described the 
stress   response   to  laryngoscopy and tracheal intubation in the year  
1951.  They proposed that the cardiac dysrhythmias, hypertension and 
tachycardia related to laryngoscopy and endotracheal intubation were the 
result  of  either   increased  sympathetic  activity or decreased vagal tone.  
They noted that laryngoscopy alone caused an increased blood pressure.  
Intubation augmented this effect and was capable of inducing arrhythmias. 
Wycoff  compared laryngoscopy and endotracheal  intubation under 
general anaesthesia with the same under cricothyroid block.  The block 
produced smaller changes in blood pressure and heart rate. Dingle observed 
a rise in systolic BP of more than 100mm of Hg following endotracheal 
intubation.  Timori and Widdicombe observed that mechanical stimulation 
of four areas of the upper respiratory tract, the epipharynx, the 
laryngopharynx , tracheobronchial tree and the nose induced reflex 
cardiovascular response.  
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                  Puri GD and Batra YK in 1988 conducted a study on effect 
of sublingual nifedipine in reducing the haemodynamic response 
due to laryngoscopy and tracheal intubation. They conducted the 
study on 40 patients who were divided into two groups to receive 
either 10mg nifedipine sublingualy or 10 mg placebo capsules ten 
minutes before induction. They found that sublingual nifedipine is 
effective in reducing the stress response due to laryngoscopy and 
tracheal intubation. The placebo group had a significant increase in 
BP and HR. However HR increased significantly in both group 
following laryngoscopy and tracheal intubation. 
 
             Nishikawa T,Namiki A in 1989 studied the effect of iv 
verapamil in reducing the stress response following intubation and 
laryngoscopy. They gave .1mg/kg verapamil to the study group just 
after induction. They made a continuous monitoring of the MAP 
and HR. They concluded from their study that iv verapamil is 
effective in reducing the pressor response following laryngoscopy 
and intubation. This reduction in pressor response was more 
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evident in the hypertensive group. The HR was comparable in both 
groups 
                   O’Sullivan G et. al in 1980  conducted a study to 
demonstrate the effect of droperidol 150mcg/kg in reducing the 
haemodynamic response to laryngoscopy and intubation. In their 
study they gave iv droperidol 150mcg/kg before anaesthesia. They found 
that MAP was significantly lower in the droperidol group compared to the 
control group  
 
                    Mikawa et .al in 1990 conducted a study to evaluate the effect 
of iv diltiazem .2 to .3mg/kg in reducing the stress response following 
laryngoscopy and tracheal intubation. They conducted the study in a  group 
of  patients of  20.They gave iv diltiazem to the test group sixty seconds 
before laryngoscopy. The control  group received saline instead The study 
showed that MAP and rate pressure product was significantly increased in 
saline group and iv diltiazem is a simple and effective  drug in attenuating 
the cardiovascular response associated with intubation. 
 
                   Mikawa et.al in 1991 studied the efficacy of ATP   .05-.1mg/kg  
in reducing the stress response associated with tracheal intubation and 
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laryngoscopy. They choose 20 patients for the study.  A test group 
consisting of 10 patients received .05-.1mg/kg of   ATP as iv bolus 
simultaneously with laryngoscopy. The control group  were given iv saline. 
The study showed that the MAP and rate pressure product were increased 
significantly in the control group of patients who received iv saline. There 
was a significant reduction in the MAP and rate pressure product of   the 
test group. The study showed that  the use of  iv ATP  is a simple and 
practical method to  blunt the effect of  stress response following  
laryngoscopy and tracheal intubation. 
 
                   Mikawa et.al in 1991 conducted another study to demonstrate 
the efficacy and safety of  iv NTG in reducing the stress response due to 
laryngoscopy and endotracheal intubation. The study was conducted on a 
group of 30 patients who belongs to ASA I category. They were divided 
into 3 groups of  ten patients. First group received normal saline iv ,the 
second group were given iv NTG 1.5mcg/kg and the third group was 
injected with iv NTG 2.5mcg/kg. NTG was given as a rapid iv bolus 
simultaneously   with the starting of laryngoscopy. The study found that 
there was a significant rise in MAP and rate pressure product in the saline 
group associated with laryngoscopy and intubation  whereas both  MAP 
and rate pressure product are significantly lower in the NTG group. The 
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study concluded that  a rapid iv dose of  NTG is effective in reducing the 
haemodynamic response due to laryngoscopy and endotracheal intubation. 
 
                   Marashi SM et.al in 2009 conducted a comparative study to 
demonstrate the effect of  clonidine .2mg, gabapentin 900mg and placebo 
on hyperdynamic response associated with laryngoscopy and tracheal 
intubation. The study was done on 75 ASA I and ASA II patients who were 
divided into 3 groups to receive either .2mg clonidine,900mg gabapentin or 
placebo  2hr before  surgery. The study concluded that both gabapentin and 
clonidine are effective in blunting the haemodynamic response following 
laryngoscopy and endotracheal intubation. In the study placebo group 
showed a rise in SBP,DBP,MAP and HR following laryngoscopy and 
subsequent intubation. 
 
                       Achola KJ et.al in 1988 studied the catecholamine and 
circulatory response to laryngoscopy and endotracheal intubation and the 
role of  beta antagonists in blunting these effects. They conducted the study 
in 20 patients who were given either practolol 10mg or saline just before 
induction. .SBP,HR and plasma adrenaline concentrations were monitored 
before and after laryngoscopy and intubation. The Study concluded that 
SBP, HR and plasma adrenaline  all showed a rising trend following 
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laryngoscopy and intubation. The study also showed that  practolol  is not 
effective in attenuating the stress response following tracheal intubation.  
 
                   Luizos AA et.al in 2007 conducted a study on the effect of 
esmolol in controlling the haemodynamic response  associated with 
laryngoscopy and intubation in cigarette smokers. The study was done on 
165 patients who are known smokers. They were divided into 2 groups to 
receive either esmolol 2mg/kg 2 minutes before laryngoscopy or placebo. 
The  study showed a significant rise in SBP and HR IN the control group 
were as the esmolol group demonstrated a stable haemodynamic status 
following laryngoscopy  and tracheal intubation. The study concluded that 
esmolol 2mg/kg is effective in controlling the cardiovascular response 
following tracheal intubation in smokers. 
 
                   Kautto UM in 1982 studied the efficacy of fentanyl in different 
doses to blunt the cardiovascular response associated with tracheal 
intubation.45 patients were divided into 3 groups to receive  fentanyl 
2mcg/kg ,fentanyl 6mcg/kg or placebo before  induction. The study noticed  
that there was a significant rise in SBP and HR  in the placebo group 
whereas  the group who received fentanyl 2mcg/kg showed a reduction in 
the stress response  following laryngoscopy  and intubation .The third 
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group who received fentanyl at the dose of 6mcg/kg showed complete 
abolition of stress response associated with tracheal intubation. 
 
                     Shirbman AJ et.al in 1987 conducted a study to demonstrate 
the cardiovascular response due to laryngoscopy with or without tracheal 
intubation.24 patients were selected for the study who were divided into 2 
groups. Laryngoscopy was done  in both groups for 10 seconds while one 
group of patients were intubated after laryngoscopy.SBP ,HR and plasma 
catecholamines were recorded before and after the procedure. The study 
concluded that laryngoscopy is associated with an  increase in SBP and 
plasma catecholamine level while tracheal intubation is associated with an 
increase in SBP,HR and plasma catecholamine level. 
 
                      Riad and Moussa in 2008 conducted a study on the effects 
of preoperative iv lornoxicam on elderly patients. In this study 50 
patients aged between 65 and 75 were selected .They were divided 
into two groups to receive  iv lornoxicam 8mg or placebo. They 
were given either lornoxicam or placebo 30 min before surgery. SBP, 
DBP, MAPand HR were recorded before tracheal intubation and one 
,three, five and ten minutes after intubation. They concluded from 
their study that preoperative administration of iv lornoxicam is 
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useful in reducing the stress response following laryngoscopy and 
tracheal intubation  in elderly patients. 
              
                       M.Dabiss et.al in 2010 conducted a study to demonstrate the 
effect of 16mg iv lornoxicam on cardiovascular stress response and level of 
serum catecholamine following laryngoscopy and intubation.50 patients 
were chosen for the study..They were randomly divided into  two groups to 
receive intravenous injection (i.v) of either Lornoxicam 16 mg diluted in 
4ml saline or 4ml normal saline half an hour before induction of 
anaesthesia Their results showed a significant increase in the 
haemodynamic parameters and serum catecholamine in the control group. 
They concluded that 16mg iv lornoxicam is effective in blunting the 
cardiovascular stress response following laryngoscopy and intubation.  
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              ANATOMY OF THE AIRWAY 
 
                       
 
                               Fig.1Anatomy of airway 
                 The nose warms, filters, and humidifies incoming air and is the 
organ of smell. It consists of the external nose and the internal nasal cavity. 
The nasal cavities are divided by the nasal septum, which is frequently 
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deviated with the consequence that the nasal cavities are narrowed or 
obstructed. The roof of the nasal cavity is the cribriform plate, a thin bone 
that is easily fractured, thereby resulting in communication between the 
nasal and intracranial cavities. The bony lateral wall of the nasal cavity is 
the origin of the three bony turbinates that project into the nasal cavity. 
They are easily damaged by force during the passage of nasotracheal tubes. 
Openings in the lateral wall communicate with the paranasal sinuses. 
Prolonged nasotracheal intubation impairs drainage through these 
openings, causing sinusitis. The lining of the nasal cavity is very vascular, 
and application of nasal vasoconstrictors to shrink the mucosa and dilate 
the airway reduces the risk of haemorrhage during the insertion of airway 
devices or tracheal tubes. 
              The roof of the mouth is bounded by the alveolar arch and teeth 
and consists of the hard palate anteriorly and the soft palate posteriorly. 
The tongue makes up most of the floor of the mouth, which is bounded by 
the mandible and teeth. Nonencapsulated lymphoid tissue on the posterior 
surface of the tongue (lingual tonsil) is part of the ring of Waldeyer. This 
tissue is important in that hypertrophy can cause serious difficulty in 
airway management.
 
 The ability to achieve good mouth opening is 
important for many airway procedures. Initial mouth opening is achieved 
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by rotation within the temporomandibular joint (TMJ) and subsequent 
opening by sliding (also known as protrusion, translocation, or subluxation) 
of the condyles of the mandible within the TMJ. The jaw-thrust maneuver 
uses the sliding component of the TMJ to move the mandible and attached 
structures anteriorly. The scissors maneuver  achieves maximum mouth 
opening by the application of internal pressure on the teeth to achieve both 
TMJ movements. It can facilitate the insertion of oropharyngeal airways, 
supraglottic airway devices (SADs), and laryngoscopes. All movements of 
the TMJ should be firm but gentle to minimize the risk of joint damage. 
                     The pharynx is a fibromuscular tube that extends from the 
base of the skull to the lower border of the cricoid cartilage. It joins the 
nasal and oral cavities above with the larynx and esophagus below. Both 
the pharynx and esophagus can be perforated by blind attempts at tracheal 
intubation. The nasopharynx is the part of the pharynx that lies posterior to 
the nose. Nasotracheal tubes can impinge on the posterior wall of the 
nasopharynx, and application of increasing force when resistance is met 
can cause submucosal passage of the tube. 
                   The larynx is situated at the upper end of the respiratory tract, 
where it extends from the epiglottis to the lower end of the cricoid 
cartilage. It evolved as a valve to protect the lower respiratory tract from 
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alimentary contents and later developed into an organ of speech. The 
larynx bulges posteriorly into the laryngopharynx, with the piriform fossa 
lying on each side. The larynx consists of a framework of articulating 
cartilage connected by fascia, muscles, and ligaments. It is suspended from 
the hyoid bone by the thyrohyoid membrane. The principal cartilages are 
the thyroid, cricoid, and posterior (arytenoid, corniculate, and cuneiform) 
cartilage and the epiglottis. The cricoid cartilage is a complete ring that 
articulates with the thyroid and arytenoid cartilage. The arytenoid cartilage 
sits on the posterolateral border of the cricoid, from where it can be 
dislocated during airway management. The laryngeal inlet is bounded by 
the epiglottis, aryepiglottic folds, posterior cartilage, and interarytenoid 
notch. The vocal cords run between the vocal processes of the arytenoid 
cartilage and the posterior surface of the thyroid cartilage. The lower end of 
the leaf-shaped epiglottis is attached to the middle of the posterior surface 
of the thyroid cartilage. The anterior surface is connected to the hyoid bone 
by the hyoepiglottic ligament and to the tongue by the median 
glossoepiglottic fold. The valleculae (often called vallecula) are 
depressions between the median and lateral glossoepiglottic folds that 
connect the lateral edges of the epiglottis to the base of the tongue. The 
Macintosh technique of laryngoscopy involves insertion of the tip of the 
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laryngoscope into the vallecula, where it tensions the hyoepiglottic 
ligament to achieve indirect elevation of the epiglottis. 
                         During swallowing the larynx is protected by several 
mechanisms. The larynx is tucked up behind the tongue, and the epiglottis 
diverts food away from the laryngeal inlet. The laryngeal muscles can be 
grouped according to their actions on the vocal cords: abductors, adductors, 
and regulators of tension. Motor innervation to these muscles and the 
sensory innervation of the larynx are supplied by two branches of the vagus 
nerve: the superior and recurrent laryngeal nerves. The superior laryngeal 
nerve can be anesthetized at the point where it passes through the 
thyrohyoid membrane. The recurrent laryngeal nerve can be damaged 
during surgery on the thyroid gland or by pressure from a cuff that lies just 
below the vocal cords. 
                          The cricothyroid membrane joins the thyroid with the 
adjacent cricoid cartilage. It is close to the skin, relatively avascular, and 
the widest gap between the cartilage of the larynx and trachea, so it 
provides the best access for percutaneous airway rescue techniques. It is 
normally easy to palpate, but identification may not be possible in obese 
patients. In patients with fixed neck flexion, the cricothyroid membrane 
may lie behind the sternum. 
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                  The trachea extends from the lower edge of the cricoid cartilage 
to the carina. It consists of U-shaped cartilage joined by fibroelastic  tissue 
and is closed posteriorly by the longitudinal trachealis muscle. The tracheal 
rings and trachealis  muscle are responsible for the characteristic 
endoscopic appearance of the trachea. 
                          DIRECT LARYNGOSCOPY 
             
 
                                         Fig 2.Alignment of axes     
              Direct laryngoscopy is used to facilitate tracheal intubation under 
vision. Successful direct laryngoscopy depends on achieving a line of sight 
from the maxillary teeth to the larynx. The tongue and epiglottis are the 
anatomic structures that intrude into the line of sight. Management of the 
tongue and epiglottis is therefore central to successful direct laryngoscopy. 
Before the laryngoscope is inserted, the patient is normally placed in the 
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“sniff” position . The direct laryngoscope is then used to displace the 
tongue and epiglottis out of the line of sight. The tongue is displaced 
horizontally (normally to the left) from the line of sight, the hyoid bone and 
attached tissues are moved anteriorly, and the epiglottis is elevated directly 
or indirectly to reveal the larynx. The force applied to the laryngoscope 
handle should lift the hyoid bone and attached tissues parallel to the line of 
sight. Adequate lifting force, which may cause considerable tissue 
distortion,
 
is a key factor in successful direct laryngoscopy.
 
 It is important 
to achieve the best possible view of the larynx without causing tissue 
trauma. It is not always possible to achieve line of sight with direct 
laryngoscopy. 
                         The theoretical basis of the head and neck position used for 
direct laryngoscopy was attributed to the need to align the axes of the oral 
cavity, pharynx, and larynx on the basis of a radiology study. Magnetic 
resonance imaging in awake patients has been used to challenge this 
hypothesis, but the conclusions have been controversial. Understanding of 
management of the tongue and the epiglottis is more likely than the axis 
alignment hypothesis to improve direct laryngoscopy technique. 
                      The “sniff” position  is usually the best starting position for 
direct laryngoscopy. In the sniff position, the cervical spine below C5 is 
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relatively straight, there is increasing flexion from C4 to C2, and the head 
is fully extended (occipito-atlanto-axial complex).Neck flexion between C2 
and C4 is achieved by elevation of the head.  Statistical advantage of the 
sniff position over simple head extension was found in one study, except in 
the presence of obesity or limited head extension. However, the sniff 
position facilitated a view of the larynx in 4% of patients in whom this was 
not possible with simple head extension. The sniff position also improves 
pharyngeal airway patency in patients with obstructive sleep apnoea. Head 
extension facilitates insertion of the laryngoscope, reduces contact between 
the laryngoscope and the maxillary teeth, improves the view of the larynx, 
and facilitates full mouth opening. Head extension should be used unless 
there is a contraindication. 
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                     NERVE SUPPLY OF THE AIRWAY 
                           
 
                          Fig 3.Nerve supply of larynx  
 
                 The sensory supply to the upper airway is derived from the 
cranial nerves. The mucous membranes of the nose are innervated by the 
ophthalmic division (V1) of the trigeminal nerve anteriorly (anterior  
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ethmoidal nerve) and by the maxillary division (V2) posteriorly 
(sphenopalatine nerves). The palatine nerves provide sensory fibers from 
the trigeminal nerve (V) to the superior and inferior surfaces of the hard 
and soft palate.  
                                  
 
                             Fig 4.Nerve supply of airway 
                  The lingual nerve (a branch of the mandibular division [V3] of 
the trigeminal nerve) and the glossopharyngeal nerve (the ninth cranial 
nerve) provide general sensation to the anterior two-thirds and posterior 
third of the tongue, respectively. Branches of the facial nerve (VII) and 
glossopharyngeal nerve provide the sensation of taste to those areas, 
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respectively. The glossopharyngeal nerve also innervates the roof of the 
pharynx, the tonsils, and the under surface of the soft palate. The vagus 
nerve (the tenth cranial nerve) provides sensation to the airway below the 
epiglottis. The superior laryngeal branch of the vagus divides into an 
external (motor) nerve and an internal (sensory) laryngeal nerve that 
provide sensory supply to the larynx between the epiglottis and the vocal 
cords. Another branch of the vagus, the recurrent laryngeal nerve, 
innervates the larynx below the vocal cords and the trachea. 
   Macintosh Laryngoscope and Technique of Orotracheal Intubation  
                 The Macintosh curved laryngoscope is radically different from    
the   pre-existing straight laryngoscopes. In particular, the long axis of the 
blade is curved, the cross section is a right-angled “Z” section, the web and 
flange are bulky, the tip is atraumatic, and the light bulb is shielded by the 
web. However, Macintosh's key innovation was his novel technique of 
indirect elevation of the epiglottis, achieved by tensioning the hyoepiglottic 
ligament after the tip of the laryngoscope was positioned in the vallecula. 
This technique is the key to success of the Macintosh laryngoscope—and 
its fundamental flaw. When it works well, the epiglottis is elevated 
completely and lies behind and along the posterior surface of the 
laryngoscope blade. However, it is not possible to position the Macintosh 
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laryngoscope correctly in some patients. Minor difficulty results in partial 
elevation of the epiglottis, erroneously described as a “floppy epiglottis,” 
and major difficulty leads to complete failure to elevate the epiglottis with 
the consequence that the vocal cords cannot be seen. 
                    Tracheal intubation is normally achieved with a rapid sequence 
of maneuvers in which all components of a complex technique merge into 
one another. The best technique will develop if all components are 
optimized. The three component steps of direct laryngoscopy are insertion 
of the laryngoscope, adjustment of its position and lifting force, and use of 
other maneuvers to optimize the view of the glottis. 
             The “sniff” position is used. Full mouth opening facilitates 
insertion of the laryngoscope. It is inserted from the right side of mouth and 
to the right of the tongue while taking care to not trap the lips between the 
laryngoscope blade and the teeth. The laryngoscope is advanced and 
simultaneously moved into the midline to displace the tongue to the left. 
Progressive visualization of anatomic structures minimizes the risk of 
trauma. The epiglottis is the first key anatomic landmark. The tip of the 
laryngoscope is advanced into the vallecula, and the epiglottis is elevated 
indirectly by applying a force that tensions the hyoepiglottic ligament. 
Elevation of the epiglottis is optimized and a further lifting force is applied 
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to the laryngoscope to achieve the best view of the larynx . It is very 
important not to lever on the maxillary teeth because this may cause dental 
damage and reduce the view of the larynx. If visualization of the larynx 
cannot be achieved without pressure on the teeth, use of this laryngoscope 
should be abandoned and another technique of tracheal intubation  used. 
                      When a good view of the larynx is achieved, the vocal cords, 
aryepiglottic folds, posterior cartilage, and interarytenoid notch can be 
identified . The view should be optimized to facilitate passage of the 
tracheal tube. If the view of the larynx is poor, it is important to check that 
the basic technique has been performed optimally and other maneuvers  
used . External laryngeal manipulation (better described as “bimanual 
laryngoscopy,” which implies internal movement of the laryngoscope with 
external manipulation of the larynx), performed by the anaesthesiologist 
who guides an assistant , consistently improves the laryngeal view. It is a 
key  manaever. 
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                                       TABLE 1 
Maneuvers Used to Optimize the View at Direct Laryngoscopy 
 
 
  Maximum head extension 
 
  Tongue entirely to the left of the laryngoscope 
 
  Optimal depth of insertion of the laryngoscope 
 
  Strong lifting force applied in the correct direction to the 
laryngoscope 
 
  External laryngeal manipulation—applied initially with the 
right hand of the anaesthesiologist 
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                                       Tracheal Tubes  
              Tracheal tubes are designed to provide a secure channel through 
the upper airway. The distal end lies in the mid to lower part of the trachea, 
whereas the proximal end lies outside the mouth or nose, where it is 
connected to an anaesthesia circuit or other device. Tracheal tubes used in 
adult patients have a cuff near the distal end that is inflated to provide a 
seal against the tracheal wall to protect the lungs from pulmonary 
aspiration and to ensure that the tidal volume delivered ventilates the lungs 
rather than escapes into the upper airway. Cuffs are normally inflated with 
air and have an inflation tube with a pilot balloon that indicates cuff 
inflation. 
                  The size of the tracheal tube is normally described as the 
internal diameter (ID) in millimetres, but the relationship of the ID to the 
external diameter varies between different designs and manufacturers. Use 
of the largest possible tracheal tube was once considered good practice. 
Very small tracheal tubes may allow insufficient time for completion of 
exhalation and produce air trapping (“auto-PEEP”) with the risk of 
barotrauma and circulatory compromise. Others have found no evidence of 
obstruction to expiration with tube sizes as small as 6-mm ID, and the 
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increased workload created is usually of little clinical significance during 
anaesthesia. Use of small tracheal tubes reduces the incidence of sore throat 
and hoarseness. Small tracheal tubes are easier to insert than larger tubes 
and may cause less tissue pressure at the larynx. It is easier to pass small 
tracheal tubes over introducers or FFLs. Restriction of gas flow through a 
tracheal tube is markedly increased by the presence of an FFL or suction 
catheter within the lumen of the tracheal tube. Tracheal tube sizes of 8 mm 
(ID) for males and 7.5 mm (ID) for females are often used. 
                       Specialized tracheal tubes produced for anaesthesia include 
preformed, adjustable shape, and reinforced. Specialized tubes are also 
used for ear, nose, and throat (ENT) surgery (laser and microlaryngeal 
surgery) and for thoracic anaesthesia and critical care. Tracheal tubes can 
become kinked and hence obstructed when they are angulated. Armored 
(reinforced) tubes have an embedded coil (usually stainless steel) that 
minimizes kinking of the tube when it is subjected to angulation. Armored 
tracheal tubes are the tubes of choice in many head and neck procedures 
and patient positions other than supine. However, an armored tube that has 
been compressed remains pinched, so it is particularly important to prevent 
biting on such a tube. 
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                     The material and bevel shape of the tip of the tracheal tube 
can affect the ease and probably the trauma of tube passage. The tip of the 
earliest Magill tracheal tubes had a soft, simple bevel. The Murphy eye, a 
hole in the wall of a firm tip opposite the bevel, was designed to provide a 
patent airway if the tracheal tube became occluded at the bevel. Air leakage 
through the Murphy eye may facilitate early diagnosis of tracheal tube 
displacement before complete accidental extubation has occurred. 
                      Cuff inflation achieves a seal between the tracheal tube and 
the wall of the trachea. There should be no air leak at airway pressures 
required for positive-pressure ventilation, and the lungs should be protected 
from aspiration. The cuffs of early tracheal tubes produced a high pressure 
that could cause mucosal ischemia. High-volume, low-pressure cuffs were 
developed to conform to the D-shaped cross section of the trachea and 
provide a seal at a lower cuff pressure, thereby reducing the risk of tracheal 
damage. 
                    Inflation of the cuff with a volume that just prevents an air leak 
(“just-seal volume”) is often recommended. However, this cuff pressure 
varies greatly. Prevention of excessive cuff pressure may reduce the 
incidence of tracheal damage, vocal cord dysfunction from recurrent 
laryngeal nerve palsy, and sore throat after surgery. Because palpation is 
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not a good guide to cuff pressure, use of a monitor to maintain cuff 
pressure in the range of 25 to 30 cm H2O is recommended. 
                    Cuff pressure can change after initial inflation. Inhaled N2O 
diffuses into tracheal tube cuffs that have been inflated with air and 
increases the volume and pressure within the cuff enough to cause tracheal 
lesions and an increased incidence of sore throat. A leak in the cuff or valve 
or a reduction in trachealis muscle tone can lower cuff pressure and 
increase the risk for pulmonary aspiration. Early detection of both low and 
high pressure is important. 
                  A properly inflated cuff protects against massive pulmonary 
aspiration, but silent aspiration (micro-aspiration) of pharyngeal contents 
occurs along channels between folds in the cuff and is a major contributor 
to ventilator-associated pneumonia in intensive care. New materials and 
cuff designs attempt to eliminate cuff channels and may help prevent 
micro-aspiration. 
                                    Tracheal Intubation  
                Tracheal intubation (insertion of the tracheal tube) is an essential 
skill in anaesthetic practice. Indications for tracheal intubation are shown in 
table 2.  
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                                               TABLE 2 
  
Indications for tracheal intubation 
 
Surgical and Anaesthetic Indications  
 
  Surgical requirement for neuromuscular blocking drugs, e.g., 
abdominal surgery 
 
  Airway access shared with the surgeon, including ear, nose, 
and throat surgery 
 
  Patient position in which access to the airway is restricted or 
precludes rapid tracheal intubation, e.g., lateral, prone 
 
  Predicted difficult airway 
 
  Risk of aspiration of gastric contents or blood, e.g., upper 
gastrointestinal obstruction or sepsis, facial trauma, bleeding 
into the respiratory tract from any cause 
 
  Surgery that impairs gas exchange 
 
  Prolonged surgery 
 
  Other airway techniques ineffective 
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                                            Critical Illness  
 
  Inability to protect the airway, e.g., coma from any cause 
 
  Impaired respiratory function (hypoxemia or hypercapnia) 
unresponsive to noninvasive management 
 
  Prevention of hypercapnia, e.g., raised intracranial pressure 
 
 
 
COMPLICATIONS OF LARYNGOSCOPY & INTUBATION 
                  The complications of laryngoscopy and intubation include 
hypoxia, hypercarbia, dental and airway trauma, tube malpositioning, 
physiological responses to airway instrumentation, or tube malfunction. 
These complications can occur during laryngoscopy and intubation, while 
the tube is in place, or following extubation. 
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 TABLE 3: COMPLICATIONS OF INTUBATION 
                 
During laryngoscopy and intubation  
 Intubation of the esophagus 
 Bronchial intubation 
 Laryngeal cuff position 
 Trauma of airway 
 Damage to the teeth 
 Laceration of  lip, tongue, or mucosa  
 Sore throat 
 Dislocation of the  mandible 
 Haemodynamic response 
 
 Retropharyngeal dissection 
 Hypoxia and  hypercarbia 
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 Hypertension, tachycardia 
 ICT 
 Intraocular hypertension 
 Laryngospasm 
 Malfunctioning of the tube  
 Perforation of cuff 
While the tube is in place  
 Malpositioning of tube 
 Unintentional extubation 
 Bronchial intubation 
 Laryngeal cuff position 
 Trauma of the airway 
 Inflammation and ulceration of mucosa 
 Nasal Excoriation 
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 Malfunctioning of tube 
 Fire/explosion 
 Obstruction of tube 
Following extubation  
 Airway trauma 
 Edema and stenosis (glottic, subglottic, or tracheal) 
 Hoarseness of voice (vocal cord granuloma or paralysis) 
 Laryngeal malfunction and aspiration 
 Laryngospasm 
 Negative-pressure pulmonary oedema 
 
 
                                           Airway Trauma 
 Instrumentation with a metal laryngoscope blade and insertion of a 
stiff TT often traumatize delicate airway tissues. Although tooth damage is 
the most common cause of malpractice claims against anaesthesiologists, 
laryngoscopy and intubation can lead to a range of complications from sore 
throat to tracheal stenosis. Most of these are due to prolonged external 
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pressure on sensitive airway structures. When these pressures exceed the 
capillary–arteriolar blood pressure (approximately 30 mm Hg), tissue 
ischemia can lead to a sequence of inflammation, ulceration, granulation, 
and stenosis. Inflation of a TT cuff to the minimum pressure that creates a 
seal during routine positive-pressure ventilation (usually at least 20 mm 
Hg) reduces tracheal blood flow by 75% at the cuff site. Further cuff 
inflation or induced hypotension can totally eliminate mucosal blood flow.  
    Postintubation croup caused by glottic, laryngeal, or tracheal 
edema is particularly serious in children. The efficacy of corticosteroids 
(eg, dexamethasone—0.2 mg/kg, up to a maximum of 12 mg) in preventing 
postextubation airway edema remains controversial; however, they have 
been demonstrated to be efficacious in children with croup from other 
causes. Vocal cord paralysis from cuff compression or other trauma to the 
recurrent laryngeal nerve results in hoarseness and increases the risk of 
aspiration. Some of these complications may be decreased by using a TT 
shaped to conform to the anatomy of the airway (eg, Lindholm Anatomical 
Tracheal Tube). The incidence of postoperative hoarseness appears to 
increase with obesity, difficult intubations, and anaesthetics of long 
duration. Applying a water-soluble lubricant or an anaesthetic-containing 
gel to the tip or cuff of the TT does not decrease the incidence of 
postoperative sore throat or hoarseness. Smaller tubes (size 6.5 in women 
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and size 7.0 in men) are associated with fewer complaints of postoperative 
sore throat. Repeated attempts at laryngoscopy during a difficult intubation 
may lead to periglottic edema and the inability to ventilate with a face 
mask, thus turning a bad situation into a life-threatening one.  
 
PHYSIOLOGY AND PATHPHYSIOLOGY OF THE UPPER AIRWAY 
 
 Upper Airway Obstruction  
             In an awake patient, airway patency is maintained by muscle tone 
in the head and neck, particularly the pharynx and tongue. As 
consciousness is lost and muscle tone is reduced, tissues fall backward 
under the influence of gravity in a supine patient and can obstruct the upper 
airway. The order of importance of these obstructing tissues is the soft 
palate (velopharynx), epiglottis, and tongue. Head extension (as a 
consequence of tensioning the strap muscles) and jaw thrust move the 
hyoid bone and attached structures anteriorly and relieve airway 
obstruction to a variable extent. Jaw thrust is also effective in reducing 
obstruction at the velopharynx in slim but not in obese patients. The lateral 
position can be used alternatively or in addition to the aforementioned 
techniques to allow the obstructing tissues to move downward so that 
obstruction is reduced. 
36 
 
                     There is now evidence of an additional dynamic component of 
upper airway obstruction when consciousness is reduced. In the conscious 
state the tone of the pharyngeal muscles is increased by neural discharge 
just before phrenic nerve discharge. Loss of pharyngeal tone and collapse 
of the narrow velopharynx play an important role in upper airway 
obstruction during spontaneous ventilation in an anesthetized patient. The 
airway in the nose and nasopharynx is held open by bone and cartilage and 
in the larynx and trachea by cartilage. Dynamic collapse of the intervening 
pharynx can occur when muscle tone is reduced. The structure of a 
collapsible segment between two rigid tubes corresponds to the basic 
elements of a Starling resistor in that flow can depend on the intraluminal 
pressure gradient or on transmural pressure in the collapsible area. Flow 
through the collapsible segment depends on how the intraluminal pressure 
upstream and downstream relate to the tissue pressure around the pharynx. 
Factors that narrow the pharynx, increase pressure around it, reduce 
pressure within it, or make its walls more compliant will increase upper 
airway obstruction. The therapeutic consequence of dynamic collapse is 
that nasal continuous positive airway pressure (CPAP) reduces dynamic 
upper airway obstruction. Nasopharyngeal airways might reduce this 
dynamic airway obstruction. 
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 Laryngospasm  
             Laryngospasm (reflex closure of the true vocal cords alone or with 
the false cords because of stimulation of the intrinsic laryngeal muscles) 
can result from the combination of reflex hyperactivity at an intermediate 
depth of anaesthesia and noxious distant surgical or local stimuli. 
Laryngospasm is usually maintained well beyond the duration of the 
stimulus. It is responsible for a significant proportion of postoperative 
critical events. Morbidity and mortality may result from the immediate 
(hypoxemia and hypercapnia) and delayed (“negative-pressure pulmonary 
edema”) consequences of laryngospasm, and thus every effort should be 
made to rapidly relieve the airway obstruction caused by laryngospasm.. 
                   Negative-pressure pulmonary edema
 
 is a consequence of 
forceful inspiratory effort in the presence of a closed glottis or other cause 
of upper airway obstruction. The subatmospheric alveolar pressure 
generated promotes transudation of fluid from pulmonary capillaries into 
the interstitial space and alveoli. Small vessel damage may be responsible 
for frank hemorrhage into alveoli. Management consists of relief of the 
obstruction, oxygen therapy, and standard management of pulmonary 
edema. Most cases resolve rapidly, but reintubation and positive-pressure 
ventilation are sometimes required. 
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  Oxygenation and Preoxygenation  
            Hypoxemia can occur in the time between induction of anaesthesia 
and attainment of airway security and is particularly likely if airway 
management proves difficult. It makes sense to maximize oxygen stores 
before induction to prolong the period before the onset of hypoxemia in the 
event of serious difficulty with airway management. The principal oxygen 
stores are in the lungs. These stores can be increased by using a maneuver 
called “preoxygenation” (also known as denitrogenation), which is 
achieved by having the patient breath 100% oxygen from a close-fitting 
facemask before induction of anaesthesia. Several techniques of 
preoxygenation have been described, and the most effective technique 
should be used. Deep breathing with a high fresh gas flow for 1.5 minutes 
and tidal breathing for 3 minutes are equally effective. It is particularly 
important to avoid leaks in the circuit, which are indicated by a flaccid 
reservoir bag and absence of a normal capnograph waveform. Wherever 
possible, the end-tidal oxygen concentration should be used as a guide to 
the adequacy of preoxygenation, with a value of 90% being well accepted. 
Preoxygenation in the semi-sitting position prolongs the time to 
development of hypoxemia by increasing functional residual capacity in 
relation to the supine position, particularly in an obese patient. Use of 
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positive end-expiratory pressure (PEEP) during induction may further 
improve oxygenation. 
          PHARMACOLOGY OF AIRWAY MANAGEMENT  
              The choice of pharmacologic technique is part of the essential 
planning of airway management and will be influenced by both airway and 
surgical requirements, particularly for surgical access and neuromuscular 
blockade. Satisfactory conditions for tracheal intubation are particularly 
demanding and may be facilitated by several pharmacologic techniques, 
each of which has advantages and disadvantages. Direct laryngoscopy is 
facilitated by a reduction in tone of the head and neck muscles. A high 
success rate and low risk for laryngeal trauma are facilitated when the 
vocal cords are open and nonreactive, at the cost of reduced protection 
against pulmonary aspiration. 
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 Inhaled Induction of Anaesthesia  
            Induction plus maintenance of anaesthesia by the inhalation of 
gaseous and volatile anaesthetics was the original pharmacologic technique 
for anaesthesia. It remains an important technique in situations such as lack 
of venous access and anticipated airway difficulty in a patient who refuses 
awake techniques. A major advantage of inhaled induction of anaesthesia is 
that spontaneous ventilation is maintained while changes in the depth of 
anaesthesia and associated respiratory and cardiovascular effects occur 
gradually. Good facemask technical skills are essential to prevent airway 
obstruction and leaks around the mask. 
                 Deep anaesthesia is necessary for direct laryngoscopy and 
tracheal intubation with inhaled anaesthetics alone. It can be complicated 
by hypotension, hypoventilation, and airway obstruction. A depth of 
anaesthesia that allows controlled ventilation has been recommended when 
sevoflurane is used. Prior administration of topical anaesthesia (e.g., 4% 
lidocaine, 3 to 5 ml) can facilitate tracheal intubation under lighter inhaled 
anaesthesia. 
               Sevoflurane has advantages over other volatile anaesthetics for 
inhaled induction of anaesthesia. It has a low blood-gas partition coefficient 
and causes minimal airway irritation, which facilitates rapid smooth 
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attainment of a depth of anaesthesia sufficient for airway procedures.        
A rapid technique (“single breath”) in which the patient breathes 8% 
sevoflurane from a prefilled anaesthesia circuit has been advocated rarely 
but causes apnea more frequently than the traditional technique does. 
Furthermore, seizure activity with sevoflurane is more likely with rapid 
induction of anaesthesia. 
                Inhaled induction of anaesthesia is very useful in a wide variety 
of difficult airway conditions. Its use has been advocated in patients with 
stridor but can result in sudden airway obstruction, which prevents rapid 
reduction of the depth of anaesthesia. Relief of obstruction may be difficult 
or impossible, even when CPAP is used with mask ventilation, so 
emergency cricothyrotomy may be required. Propofol infusion, with topical 
anaesthesia before endotracheal intubation, has been used successfully for 
the management of patients with a difficult airway. Caution is required 
because apnoea can occur when propofol is infused in patients with normal 
airways. 
  Intravenous Anaesthesia with Neuromuscular Blocking Drugs  
               The combination of an intravenous anaesthetic with an NMDB is 
the pharmacologic technique most frequently used for tracheal intubation in 
routine practice . It provides good conditions rapidly in most patients 
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inasmuch as neuromuscular blockade facilitates laryngoscopy, opens the 
vocal cords, and prevents coughing. The high quality of intubating 
conditions produced by NMBDs reduces the risk for postintubation 
laryngeal damage. However, the apnea caused by this pharmacologic 
approach has disadvantages. If tracheal intubation of an apneic patient 
proves impossible, oxygenation requires effective ventilation with a 
facemask or SAD, neither of which is completely reliable. Pharmacologic 
techniques that produce apnea should not be used when difficulty with 
tracheal intubation or mask ventilation is predicted. As indicated 
previously, the use of sugammadex may alter the approaches to difficult 
intubation. 
                   In routine practice, nondepolarizing NMBDs are often 
preferable to succinylcholine to prevent its side effects . Succinylcholine is 
chosen when rapid onset and offset are important. Use of rocuronium as an 
alternative to succinylcholine has been suggested to avoid the side effects 
unique to succinylcholine. Although the duration of paralysis produced by 
rocuronium is very much longer, the use of sugammadex as a reversal 
agent makes recovery from an NMBD as quick as that from 
succinylcholine and more predictable. It is now clear that a combination of 
rocuronium and sugammadex can restore spontaneous ventilation more 
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rapidly than waiting for succinylcholine to wear off. Possibly the need for 
succinylcholine may disappear completely. 
  Intravenous Anaesthesia with Narcotics  
               The use of short-acting narcotics instead of NMBDs to facilitate 
tracheal intubation has been advocated as a means of avoiding the side 
effects of succinylcholine. This technique is effective in many patients who 
have no risk factors for difficult intubation. However, it has serious 
disadvantages. Conditions for direct laryngoscopy and tracheal intubation 
are worse than when NMBDs are used, so there is a higher frequency of 
failed intubation and airway trauma. Arterial hypotension is more likely 
when large doses of intravenous anaesthetics and narcotics are given. A 
higher incidence of laryngeal trauma when intubation is performed without 
NMBDs has been reported. Use of a large dose of narcotics when 
ventilation with a facemask or SAD is intended has other significant 
disadvantages. It may produce apnea and delay the return of spontaneous 
ventilation. More importantly, it can make ventilation of the lungs with a 
mask or SAD difficult or impossible as a consequence of vocal cord 
closure, a problem sometimes attributed to “chest wall rigidity.” The 
combination of intravenous anaesthesia with topical anaesthesia of the 
44 
 
larynx produces good conditions and may be a better alternative to the use 
of NMBDs. 
 Local Anaesthetic and “Awake” Techniques of Airway Management  
                        Tracheal intubation of a conscious patient can allow 
uninterrupted respiration and airway protection while avoiding the risk to 
airway maintenance and protection inherent with general anaesthesia. It is 
indicated when there is a possibility of difficulty with airway management. 
Tracheal intubation of a conscious patient is often called “awake” 
intubation. Good topical airway anaesthesia, rapport, and gentleness are the 
keys to success. Sedation is often used but cannot compensate for 
inadequate topical anaesthesia and is dangerous in patients with a critical 
airway. 
                     Topical anaesthesia of the airway can be used to facilitate the 
performance of many airway procedures  in a conscious patient in whom 
reduced consciousness is likely to cause difficulty in airway management. 
Direct laryngoscopy has long been used for awake intubation but is often 
difficult and can be distressing for all involved. Use of a flexible fiberoptic 
laryngoscope (FFL) for tracheal intubation under topical anaesthesia was a 
milestone in safe airway management because intubation of a conscious 
patient could now be achieved with minimal discomfort. This technique has 
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become the standard for management of an anticipated difficult airway. 
Options are preserved if awake flexible fiberoptic intubation is not 
successful, surgery can be postponed and the patient awakened, an 
unhurried surgical airway can be performed, or tracheal intubation can be 
attempted in a breathing patient (awake or inhaled induction) with other 
visual techniques.  
                                         TABLE 4 
Airway Techniques That Can Be Performed Under Topical 
Anaesthesia in an Awake Patient 
 
 
  Supraglottic airway device insertion 
 
  Direct laryngoscopy and intubation 
 
  Blind nasal intubation 
 
  Retrograde intubation 
 
  Flexible fiberoptic laryngoscopy and intubation 
 
  Rigid indirect optical devices and intubation 
 
  Tracheotomy/Cricothyrotomy” 
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                    Topical anaesthesia reduces the calibre of a normal airway. 
Use of topical anaesthesia in a patient with a compromised airway can lead 
to loss of the airway and should be performed only by experts who have a 
team prepared for immediate creation of a surgical airway. 
                      Lidocaine has a better safety profile than other agents used 
for airway anaesthesia. However, excessive doses can cause fatal toxicity. 
Administration should be titrated and the mental state of the patient 
monitored. Blood concentrations are influenced by the technique chosen, 
and aerosol delivery to the lower respiratory tract should be minimized. 
                  Several techniques of airway anaesthesia are shown in table 5 in 
the next page . Each has advantages and disadvantages. Nebulizers have 
been used to deliver topical anaesthesia to the airway. The optimum 
particle size is larger than that required for the treatment of asthma. Simple 
aerosol techniques, such as injection into oxygen flowing in a narrow tube, 
appear to work satisfactorily. Most of the inhaled solution is exhaled, and 
up to 20 minutes may be required to achieve satisfactory topical 
anaesthesia. Inhalation of an aerosol of local anesthetic is usually well 
tolerated and can anesthetize the entire respiratory tract. The quality of 
topical anaesthesia achieved with nebulizers is not as good as that achieved 
47 
 
with other techniques, but it is a useful option when other techniques 
cannot be used or coughing is particularly undesirable. 
                                         TABLE 5  
            Techniques of Airway Anaesthesia 
 
 
  Nebulizers—entire airway 
 
  Topical sprays and gels—upper airway 
 
  Transtracheal injection—larynx and trachea 
 
  “Spray as you go”—larynx and trachea 
 
  Nerve blocks—distribution of the nerve supply 
 
  Combinations of the above 
 
                 Local anesthetic sprays and gels achieve rapid topical 
anaesthesia of the nose, mouth, and pharynx. Pressurized aerosol sprays 
contain preservatives that may cause a sore throat postoperatively, and they 
are less effective than gels. Lidocaine 4% administered by a spray 
attachment for syringes is popular. The first spray is pungent and patients 
should be warned. Lidocaine gel (2%) is very effective and well tolerated, 
but subsequent optical images through the gel may be slightly impaired. 
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Most of the lidocaine applied with sprays or gels is swallowed and the 
absorbed drug metabolized in first-pass hepatic metabolism. 
                 Topical anaesthesia of the larynx and trachea may be achieved 
by transtracheal injection or a “spray as you go” (SAYGO) technique. 
SAYGO is an intermittent application technique that causes coughing and 
requires time for recovery after each application. Use of an epidural 
catheter within the working channel of the fiberscope is an effective means 
of administering SAYGO. Transtracheal injection through the cricothyroid 
membrane is more invasive but quickly produces good topical anaesthesia. 
Coughing spreads the local anesthetic. A bolus of narcotic is frequently 
given before transtracheal injection to prevent excessive coughing. 
Narcotics themselves can cause coughing, which can be suppressed by the 
inhalation of salbutamol or beclomethasone or by intravenous lidocaine. 
The quality of transtracheal anaesthesia is preferred by patients and 
endoscopists over that produced by nebulizers or SAYGO. 
                   Nerve blocks produce more profound and longer-lasting 
anaesthesia than topical anaesthesia does. A superior laryngeal nerve block 
created by injection through the thyrohyoid membrane is the least invasive 
of the airway nerve blocks and provides good anaesthesia of the area 
between the vocal cords and the epiglottis. 
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          PHYSIOLOGIC RESPONSE TO TRACHEAL INTUBATION 
              Direct laryngoscopy and passage of a tracheal tube are noxious 
stimuli that can provoke adverse responses in the cardiovascular, 
respiratory, and other physiologic systems. 
             Significant hypertension and tachycardia are associated with 
tracheal intubation under light anesthesia. The magnitude of the response is 
greater with increasing force and duration
 
of laryngoscopy. The elevation in 
arterial pressure typically starts within 5 seconds of laryngoscopy, peaks in 
1 to 2 minutes, and returns to control levels within 5 minutes. Such 
hemodynamic changes can result in myocardial ischemia but seem to cause 
little harm to most patients. However they are undesirable in patients with 
cardiac disease. 
              It is possible to separate the factors that contribute to the 
hemodynamic response. Hemodynamic changes start within seconds of 
direct laryngoscopy, and there is a further increase in heart rate and blood 
pressure with passage of the tracheal tube. Tracheal intubation through the 
ILMA causes a hemodynamic effect similar to that caused by direct 
laryngoscopy. When orotracheal intubation or NTI is performed with the 
FFL under general anesthesia without topical anesthesia of the airway, 
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hemodynamic changes are similar to those seen with the direct 
laryngoscope. 
                  Many techniques have been tried in an effort to attenuate 
adverse hemodynamic responses to intubation, but none is ideal. Prevention 
by use of an increased depth of anesthesia is attractive in theory. However, 
changes in the concentration of anesthetic agents in blood and at effector 
sites occur slowly in relation to the onset and offset of airway stimuli and 
hemodynamic responses. Use of N2O with a volatile agent may be 
beneficial. Large doses of narcotics (other than morphine), such as 
fentanyl, 6 µg/kg, suppress the hemodynamic response but risk prolonged 
respiratory depression. Aerosol or other application of topical anesthetics 
may be beneficial with a low risk of adverse effects. Application of such 
topical anesthesia may cause minor adverse hemodynamic effects, much 
less
 
than those caused by tracheal intubation. Combinations of topical 
anesthetics with other drugs such as opioids may be useful. 
                   Drugs that act primarily on the cardiovascular system have 
been studied. Many can reduce either the blood pressure or the heart rate 
response, but not both, and can cause hypotension or bradycardia. Labetalol 
and esmolol have been recommended, particularly in combination with 
narcotics. Use of such drugs is rarely indicated, however. 
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Another approach to reducing the cardiovascular response to tracheal 
intubation is to modify the technique of tracheal intubation. Awake flexible 
fiberoptic intubation with effective topical anesthesia almost eliminates the 
hemodynamic response to tracheal intubation. 
                  Direct arterial pressure monitoring throughout induction of 
anesthesia is desirable in a high-risk patient so that the anesthesiologist can 
respond to accurate, continuous hemodynamic information. Moderate 
depression of arterial pressure and heart rate before laryngoscopy might 
limit the rise in arterial pressure at the expense of initial cardiorespiratory 
depression. Prolonged attempts at laryngoscopy  should be avoided. 
Careful cardiovascular monitoring and willingness to interrupt direct 
laryngoscopy while anesthesia is deepened are keys to maintenance of 
reasonable homeostasis. 
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     PHARMACOLOGY OF LORNOXICAM 
                Lornoxicam (chlortenoxicam) is a non-steroidal anti-
inflammatory drug (NSAID) which belongs to the oxicam class with 
analgesic, anti-inflammatory and antipyretic properties.  It is 
available in oral and parenteral formulations 
  
  
                                    Molecular structure of lornoxicam 
              INDICATIONS 
1. Inflammatory diseases of the joints. 
2. Osteoarthritis 
3. Pain following surgery 
4. Sciatica injection 
5. For the relief of postoperative pain or acute painful conditions 
requiring parenteral analgesic 
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                                 MODE OF ACTION 
 Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic 
properties and belongs to the class oxicams.  Lornoxicam inhibits synthesis 
of prostaglandins via inhibition of cyclooxygenase enzyme. In vitro the 
inhibition of cyclooxygenase does not result in an increase in leukotrienes 
formation.  The mechanism of the analgesic action of lornoxicam has not 
been fully determined.  
Lornoxicam inhibits both isoforms that is, COX-1 inhibition: COX-2 
inhibition=38. It readily penetrates into the synovial fluid. 
Synovial fluid : plasma AUC ratio is 0.5 after administration of 4 mg twice 
daily.  
 
                                   PHARMACOKINETICS 
                                          ABSORPTION  
           Lornoxicam is absorbed rapidly and almost completely from 
the gastrointestinal tract.  Maximum plasma concentrations are achieved 
after approximately 1 to 2 hours of oral therapy. Lornoxicam Injection is 
intended, for intravenous or intramuscular administration.  After 
intramuscular injection maximum plasma concentrations are achieved after 
approximately 20-25 minutes 
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                                            DISTRIBUTION 
 The absolute bioavailability of Lornoxicam is  90-100%. No first - 
pass effect was observed. 
 
                                              METABOLISM 
 Better safety profile regarding renal and hepatic function tests, 
 Better gastrointestinal tract tolerability compared to selective COX-2 
inhibitors 
       Lornoxicam is found  in the plasma in unchanged form and as its 
hydroxylated metabolite. The hydroxylated metabolite exhibits no 
pharmacological activity. CYP2C9 has been shown to be the primary 
enzyme responsible for the biotransformation of the lornoxicam to its 
major metabolite, 5-hydroxylornoxicam. Recently, it was reported that 
lornoxicam 5'-hydroxylation by the variant CYP2C9*3 and CYP2C9*13 
was markedly reduced compared with wild type, both in vitro and in vivo. 
 
                                              ELIMINATION 
 Approximately 2/3 is eliminated via the liver and 1/3 via the kidneys 
as inactive substance.  
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                                 DRUG INTERACTIONS 
 Anticoagulants/ Sulphonylureas 
 Diuretics/ACE inhibitors / Digoxin 
 Lithium  
 Methotrexate/Cylosporin 
 Cimetidine 
 
                          DOSAGE AND ADMINISTRATION 
       Lornoxicam injections are supplied for intramuscular or 
intravenous administration.  Lornoxicam 8 mg powder for injection has to 
be dissolved in 2 ml water for injection immediately prior to use. 
Lornoxicam must be administered  as an intramuscular (5 seconds) or 
intravenous (>15 seconds) injection. Lornoxicam may exclusively be 
injected by a trained medical/paramedical personal.  After preparation of 
the solution, change the needle. For intramuscular injection use a 
sufficiently long needle for a deep intramuscular deposition of the drug.  
The total daily dose should not exceed 24 mg. 
 
       Lornoxicam is a potent NSAID from the chemical class of 
oxicams, and is marketed in a number of European countries for the 
treatment of various painful conditions associated with inflammation.  In 
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contrast to the other oxicams, lornoxicam has a very short half-life 
(approximately 4 hours as compared with >24 hours for the others) and is 
therefore especially suitable for short-term treatment.  The short half-life of 
the drug probably explains the improved gastrointestinal safety profile 
observed with lornoxicam.  A quick-release formulation of lornoxicam has 
also been developed. 
 
                        USE IN SPECIAL POPULATIONS 
                                PEDIATRIC PATIENTS 
 No pharmacokinetic data available in pediatric patients.                             
 
                         HEPATIC INSUFFICIENCY  
                   There is no significant change in the kinetic profile of 
lornoxicam in patients with mild hepatic dysfunction. However, 
accumulation of major inactive metabolite occurred in patients with hepatic 
dysfunction.  For patients with hepatic impairment the maximal 
recommended daily dose is reduced to 12 mg.  Careful clinical monitoring 
and laboratory assessment at regular intervals is recommended.                
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                                    RENAL INSUFFICIENCY 
                   There is no significant change in the kinetic profile of 
lornoxicam in patients with mild kidney dysfunction (Creatinine Clearance 
, 60 ml/min), however no data on multiple doses appear to be available. 
Dosage limitation of the drug may compensate for reduced renal 
elimination in those with severe renal dysfunction. However, clinical 
significance of this is unknown.  
                            PREGNANCY AND LACTATION 
                    No clinical data on exposed pregnancy & lactation are 
available for lornoxicam.  The potential for human risk in pregnancy is 
unknown.  As with other drugs known to inhibit prostaglandin synthesis, an 
increased incidence of dystocia and delayed parturition occurred in rats.  
No clinical data on use during labor is available.  Administration of 
lornoxicam is not recommended during labor and delivery  
 
                                     GERIATRIC USE 
 No special dosage modification is required for elderly patients, 
unless renal or hepatic function is impaired, in which case the daily dosage 
should be restricted.   
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                    CONTRAINDICATIONS & PRECAUTIONS 
     Lornoxicam is contraindicated in following 
1. Allergy to lornoxicam. 
2. (bronchospasm, rhinitis, angioedema or urticaria) to other non-
steroidal anti-inflammatory medicines, including, acetylsalicylic acid 
3. History of gastrointestinal bleeding, cerebrovascular bleeding 
4. Patients with bleeding disorders 
5. Patients with history of recurrent peptic ulceration 
6. Patients with  severe hepatic or renal insufficiency 
7. Patient with thrombocytopenia 
8. Patients with severe cardiac failure 
9. Pregnancy & Lactation. 
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                  ADVERSE EFFECTS OF LORNOXICAM 
 Lornoxicam has a tolerability profile characteristics of NSAIDs, with 
gastrointestinal adverse effects (pain, dyspepsia, nausea, vomiting) being 
the most common. 
 
   GENERAL: Headache, dizziness, changes in appetite, edema,allergic 
                         reactions                                                 
 GASTROINTESTINAL : Abdominal pain, diarrhea, dyspepsia, vomiting     
                                           gastro esophageal reflux                                               
 HAEMETOLOGICAL:  Very rarely prolonged bleeding time,    
                                          thrombocytopenia or  increased transaminases.   
 SKIN: Allergic skin reactions 
                                    STORAGE  
                       Store at temperature below 25
0
C 
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                              RELEVANCE OF THE STUDY 
 
                    Laryngoscopy and subsequent tracheal intubation result in the 
activation of the sympathetic nervous system due to stimulation of somatic 
and visceral nociceptive afferents of the airway. This leads to 
cardiovascular stimulation which result in an increased blood pressure and 
heart rate. Various  techniques have been tried to prevent or attenuate 
hemodynamic responses due to  laryngoscopy and endotracheal intubation. 
Among them  opioids,alpha-2-agonists,iv NTG, beta-blockers etc have 
been shown to be effective agents in blunting stimulatory effects on cardio 
vascular system. Unfortunately most of these agents are having  well 
known side effects.  Hence minimizing the peri-operative adverse events is 
of utmost importance. There for other agents have been tried, to replace or 
to reduce the use of these agents.  
 
 This study is to demonstrate the effect of pre operative 
administration of lornoxicam on hemodynamic changes during 
laryngoscopy and tracheal intubation.  
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 Simple and practical method of stress response attenuation. 
 Well tolerated with few adverse  effects. 
 Already being used in the treatment of  acute postoperative pain and 
to reduce the postoperative use of opioids. 
 Studies on haemodynamic effects needed before it is routinely used 
as  an agent for attenuation of stress response.   
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PATIENTS AND METHODS 
 
STUDY DESIGN  
 Single - blind randomized placebo-controlled trial 
 
INCLUSION CRITERIA 
1. Patients  who required tracheal intubation for elective surgical 
procedures 
2. ASA Class I and Class II 
3. Age between 18 & 50 years 
4. Weight of patients 40 - 70 kg 
 
EXCLUSION CRITERIA 
1. Anticipated difficult intubation. 
2. At risk of regurgitation or pulmonary aspiration 
3. With renal or hepatic impairment 
4. Taking drugs  known to affect BP & HR 
5. Allergy to NSAIDS 
6. ASA Physical status III or greater 
7. Acid peptic disease, Bronchial Asthma, coagulation disorders 
8. Pregnancy & Lactation 
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PLAN OF STUDY 
 After routine pre-anaesthetic check up and applying exclusion 
criteria 50 patients about to undergo general anaesthesia with endotracheal 
intubations were randomly allocated into two groups by drawal of lots. 
 
GROUP 1 -LORNOXICAM GROUP 
 This group received intravenous lornoxicam 16 mg 30 minutes 
before laryngoscopy and intubation after test dose. 
GROUP 2-CONTROL GROUP 
 This group received placebo (normal saline) intravenously 30mts 
before laryngoscopy and intubation. 
PREMEDICATION 
        Patients were not premedicated in this study. 
 
ANAESTHETIC TECHNIQUE 
 After obtaining approval from ethical committee 50 patients aged 
between 18 to 50 years, ASA class I and Class II requiring tracheal 
intubation for elective surgical procedure were enrolled in this randomized 
single blind placebo controlled study. All patients included in the study 
were fasted overnight from 10 pm.  In the holding area an IV cannula is 
inserted and Lactated ringers infusion was started with standard 
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monitoring. Based on randomization , the patients received either 
lornoxicam 16mg iv or placebo (iv saline) half an hour before surgery after 
obtaining informed consent from the patient and the relatives. 
Randomization was done in the preoperative holding area  by the 
anaesthesiologist who is to administer the trial drug/placebo. 
 
            Medications iv lornoxicam or normal saline will be administered by 
a different anesthetist who is not involved in the study. Induction technique 
will be standardized. On arrival in operating room and  after 
preoxygenation using Bain's co-axial circuit, anaesthesia will be induced 
with propofol 2 mg/kg. Succinyl Choline 2mg/kg will be given to facilitate 
tracheal intubation. Systolic and diastolic BP, Mean arterial pressure, heart 
rate and ECG changes will be recorded before and after administration of 
the intra-venous anaesthetic and at 1,3,5 and 10 minutes after laryngoscopy 
and tracheal intubation.  During observation period: 
  PARAMETERS COMPARED 
 Systolic blood pressure (SBP) 
 Diastolic blood pressure (DBP) 
 Mean arterial pressure (MAP) 
 Heart Rate(HR) 
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             After the documentation of results of all the fifty patients,the 
anesthesiologist who has administered the injections , revealed the identity 
of the drug. Based on this, results were analyzed as lornoxicam group and 
placebo group.                         
                      STATISTICAL TECHNIQUES 
              Data was entered in Microsoft Excel and statistical analysis done 
in SPSS. Student's test was used to analyze demographic profile, heart rate 
changes, pressure changes.  Student's 't' test is used for comparing means of 
two populations.  
P value > 0.05 is not significant 
  < 0.05 is significant 
  < 0.01 is highly significant                                             
Intubation time is defined as period from termination of manual ventilation 
using a face mask to restarting of ventilation through endotracheal tube. 
Patients requiring >20 sec to achieve successful tracheal intubation are 
excluded from the study.   
 
              Anaesthesia was maintained using 02 & N20 Mixture and 
supplemented with intravenous agents as necessary and a non-depolarizing 
muscle relaxant is used to maintain muscle relaxation. After surgery after 
meeting all criteria of reversal, patients are reversed with Inj. Neostigmine 
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0.05 mg/kg and Inj. Glycopyrrolate 8mcg/kg. Patients were observed for 24 
hours for any nausea, vomiting allergic reactions and urine output. 
 
                              OBSERVATIONS AND RESULTS 
 Fifty patients each with similar characteristics were divided into two 
groups of 25 each, one being the lornoxicam group and the other placebo 
group. 
 Two groups were perfectly matched in terms of no. of patients, age, 
sex, weight, height, ASA physical status and Duration of laryngoscopy. 
 
DEMOGRAPHIC DATA 
MATCHING 
 Group 2 (Saline) Group 1 (Lornoxicam) 
No. of patients 25 25 
Age 31.12+/.5.1 32.16+/-4.3 
Sex M/F 10/15 12/13 
Weight 57.72+/-4.1 58.9+/-5.4 
Height 166.44 ±6.4 167.2±4.5 
ASA I/II 11/14 12/13 
Duration of Laryngoscopy 14.48 (1.7) 15.48 (1.1) 
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SYSTOLIC BLOOD PRESSURE CHANGES 
Systolic blood pressure changes before and after laryngoscopy and 
intubation is analyzed and shown in Table 6. 
TABLE 6 
Systolic BP (Mean) Lornoxicam group Placebo group P Value 
Before Laryngoscopy 112.48 113.92 0.6723 
1mt 121.6 135.92 0.0001 
3mt 116 127.92 0.0213 
5mt 114.16 115.12 0.74 
10mt 113.12 114.64 0.5715 
 
Percentage of rise in systolic BP in both groups at 1 minute  
Systolic BP Lornoxicam group Placebo group 
1mt 8% 19.3% 
 
 From graph 1 it is evident that systolic BP before laryngoscopy after 
induction was comparable in both groups but there was definite reduction 
in stress response in lornoxicam group and difference was significant at 1 
minute and 3 minute intervals. 
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Graph-1… SYSTOLIC BP CHANGES  
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DIASTOLIC BP CHANGES 
Diastolic Blood pressure changes analyzed and shown in Table 7 
TABLE 7 
Diastolic BP Lornoxicam group Placebo group P Value 
Pre- Laryngoscopy 68.08 69.2 0.48 
1mt 72.52 81.44 0.0001 
3mt 66.24 76.4 0.0001 
5mt 64.44 70.64 0.0007 
10mt 64.96 70.32 0.001 
 
Percentage of rise in Diastolic BP in both groups at 1 minute  
Diastolic BP Lornoxicam group Placebo group 
3mt 6.5% 17.7% 
 
 
There was a significantly reduction in diastolic BP in lornoxicam group 
when compared with placebo in response to laryngoscopy and intubation. 
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              Graph -2 DIASTOLIC BP CHANGES 
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                           MEAN ARTERIAL PRESSURE 
Table 8 Compares the changes in mean arterial pressure for both the 
groups.  Mean arterial pressure is calculated using the formula. 
MAP = DBP + 1/3 (SBP-DBP) 
Where, DBP = diastolic blood pressure, SBP=systolic blood pressure. 
TABLE  8 
MAP (Mean) Lornoxicam 
group 
Placebo group P Value 
After Induction 82.88 84.1 0.46 
1mt 88.88 99.75 0.13 
3mt 82.82 93.57 0.0001 
5mt 81.01 85.47 0.0007 
10mt 81.01 85.09 0.01 
 
Percentage of rise in MAP in both groups at 1 minute 
MAP Lornoxicam group Placebo group 
1mt 7.14% 18.6% 
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Graph -3 
MAP CHANGES 
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                                     HEART RATE CHANGES 
Heart Rate changes during various stages of anaesthesia induction is 
analyzed and shown in Table 9. 
                                             TABLE 9 
MAP (Mean) Lornoxicam 
group 
Placebo group P Value 
Pre 
Laryngoscopy 
88.72 87.04 0.54 
1mt 95.84 114.16 0.001 
3mt 89.6 112.76 0.001 
5mt 83.76 101.4 0.001 
10mt 84 91.96 0.003 
 
Percentage of rise in HR  in both groups at 1 minute 
MAP Lornoxicam Placebo 
1mt 8% 31.1% 
 
Heart rate followed the same path as diastolic BP.  Rise in heart rate was 
significantly lower in lornoxicam group and difference was significant at I 
minute, 3 minute, 5 minute and 10 minute intervals. 
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Graph-4… HEART RATE CHANGES 
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 STATISTICAL  EVALUATION AND SUMMARY 
 
                                                  TABLE 10 
              Significant 
attenuation in rise of 
1mt 3mt 5mt 10mt 
Systolic BP 0.0001+ 0.02+ 0.74X 0.57X 
Diastolic BP 0.0001+ 0.0001+ 0.0007+ 0.001+ 
MAP 0.13X 0.0001+ 0.007+ 0. 01+ 
Heart Rate 0.0001+ 0. 001+ 0. 001+ 0.003+ 
 
                    Prelaryngoscopic Blood pressure and heart rate was 
comparable in both lornoxicam and control group but after laryngoscopy, 
there was definite reduction in systolic BP, diastolic BP, Mean arterial 
pressure and heart rate in lornoxicam group and the difference was 
significant at 1mt and 3mt in case of systolic BP 1mt 3mt 5mt 10mt in case 
of diastolic BP 3mt 5mt and 10mt in case of mean arterial pressure 1mt 3mt 
5mt and 10mt in case of heart rate. 
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                                         SIDE EFFECTS 
1. Two out of 50 patients developed allergic reaction  on test dose and 
            were excluded from the study.               
2. Urine output was normal in both groups postoperatively for 24 
 hours. 
3. No one developed nausea and vomiting.  
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DISCUSSION 
 
 Lornoxicam is a nonsteroidal anti-inflammatory drug of Oxicam 
class with analgesic and anti-inflammatory property.  It acts by inhibiting 
synthesis of prostaglandins via inhibition of cyclo- oxygenase but does not 
inhibit 5-lipo-oxygenase.  Lornoxicam may be administered orally, 
intramuscularly or intravenously.  After intramuscular injection maximum 
plasma concentration is achieved approximately after 20-25 minutes.  The 
absolute bioavailability after IM injection is 97%.  It is present  in plasma 
in unchanged form and as hydroxylated metabolites.  It undergoes  
extensive hepatic  metabolism   to inactive metabolite 5- hydroxy 
lornoxicam.  51% of the drug is excreted through faeces and 42% via 
kidneys with a mean elimination half life of 3-4 hours. Lornoxicam is a 
drug with very good tolerance and very low incidence of adverse effects.  
The most common among them is gastrointestinal disturbances.  Head 
ache, dizziness, allergic reactions are less common adverse reactions. 
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MECHANISM OF STRESS RESPONSE ATTENUATION BY 
LORNOXICAM 
1. Decreases serum catecholamine levels, thus obtunding                                                                                 
 cardiovascular   sympathetic response during laryngoscopy and  
           tracheal intubation. 
2. Increases endogenous opioids dynorphine and beta endorphine 
3. Prostaglandin inhibition and thus cut-off visceral and somatic 
 nociceptive afferents contributing to stress response during 
 laryngoscopy. 
 The analgesic potency of  8 mg  iv lornoxicam is equal to that of  
20mg morphine or 50mg pethidine.
 
The analgesic effect of 16mg 
lornoxicam is superior  to 100mg tramdol
 
 and was comparable to 100mcg. 
fentanyl when used as an  intraoperative analgesic in mild to moderate day 
care ENT surgeries
 
. 
 
 The haemodynamic stress response to laryngoscopy and intubation is 
supposed to be initiated by sympathetic response which starts within 5 
seconds of laryngoscope pressing the base of tongue.  It reaches the 
baseline value between 5 to 10 minutes after intubation.  In the present 
study  we have made an attempt  to determine the efficacy of intra venous 
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lornoxicam 16mg 30 minutes before laryngoscopy and intubation, in 
attenuating the haemodynamic stress response. 
. 
 In our study the  lornoxicam  group and control group were 
comparable in various parameters like age, weight,  height, sex, ASA 
grading and duration of laryngoscopy.  
 The baseline values of both groups showed no significant difference. 
Lornoxicam group has a significantly lower mean heart rate of 95.84 
compared to control group at 1 minute after intubation which showed a 
heart rate of 114.16.  Likewise lornoxicam group also has significantly 
lower heart rate at 3 minute 5 minute and 10 minutes after intubation. 
  
 In comparison with control group the lornoxicam group did not show 
rise of systolic blood pressure at 1 minute and 3 minute intervals.  Control 
showed a peak in blood pressure at 1 minute after intubation with a systolic 
BP of 135.92 at 1 minute.  The values of systolic blood pressure were near 
the baseline values at  10 minutes in both the groups. 
  
 Likewise diastolic blood pressure and mean arterial pressure of both 
groups were having an increase from basic values but the diastolic BP and 
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MAP recorded from the lornoxicam group showed a significantly lower 
value. 
  
      From the observation it is evident that the peak values reached by 
lornoxicam group are significantly lower compared to control group.  So 
we  concluded that pretreatment with 16mg intravenous  lornoxicam is 
effective in  attenuating  the cardiovascular stress response to laryngoscopy 
and tracheal intubation . Stress mediators such as endogenous plasma 
catecholamines or cortisone were not measured in our  study.  This can be 
considered as limitations of the study since measurements of endogenous 
catecholamines would  have given useful information.  As the  peri-
operative use of lornoxicam  is becoming more frequent, more studies 
which  focus on its effects on old age, ASA III & IV patients and its effect 
on stress mediators are needed. 
            COMPARISON WITH INTERNATIONAL STANDARDS 
                Riad and Moussa in 2008 conducted a study on the effects of 
preoperative iv lornoxicam on elderly patients. In this study 50 patients 
aged between 65 and 75 were selected .They were divided into two groups 
to receive  iv lornoxicam 8mg or placebo. They were given either 
lornoxicam or placebo 30 min before surgery. SBP,DBP, MAP and HR 
were recorded before tracheal intubation and one ,three, five and ten 
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minutes after intubation. The results showed a significant increase in all the 
parameters they were monitoring in the control group. They concluded 
from their study that preoperative administration of iv lornoxicam 8mg is 
useful in reducing the cardiovascular  stress response following 
laryngoscopy and tracheal intubation  in elderly patients. 
                  In agreement with the above  study our results also showed a 
significant increase in SBP,DBP,HR and MAP in the control group 
compared to lornoxicam group eventhough we used a higher dose of 
lornoxicam..Again, in comparison with the above study by Riad and 
Moussa we used lornoxicam alone while lornoxicam and fentanyl was used 
by them. This can be considered as an advantage of our study because we 
can attribute the reduction in cardiovascular parameters in lornoxicam 
group to lornoxicam alone.  
          M.Dabiss et.al in 2010 conducted a study to demonstrate the 
effect of 16mg iv lornoxicam on cardiovascular stress response and level of 
serum catecholamine following laryngoscopy and intubation.50 patients 
were chosen for the study.They were randomly divided into  two groups to 
receive intravenous injection (iv) of either Lornoxicam 16 mg diluted in 
4ml saline or 4ml normal saline half an hour before induction of 
anaesthesia .No premedications were given to the patients. An iv line was 
established and ringerlactate solution was started for all patients 30 minutes 
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before induction.  After 3 min of preoxygenation anaesthesia was induced 
with propofol 2.5mg kg. and cis-atracurium 0.15 mg/kg to facilitate 
tracheal intubation which was performed using direct laryngoscopy when 
neuromuscular block was achieved by train of four guard monitor. Baseline 
values for SBP,DBP,HR,MAP, and SpO2 were recorded and blood was 
drawn for measuring the serum catecholamine level before induction. All 
these parameters were recorded  immediately after intubation and every 
minute followed, for  ten minutes except serum catecholamine. 
 
             Their results showed a significant increase in the haemodynamic 
parameters and serum catecholamine level in the control group. They 
concluded that 16mg iv lornoxicam is effective in blunting the 
cardiovascular stress response following laryngoscopy and intubation. 
  
            The results of our study  was also in agreement with the above 
study. In our study there was a significant reduction in all the 
haemodynamic parameters following intubation in the lornoxicam group. 
In comparison with the  above study we could not measure the serum 
catecholamine levels, as the facility was not available in our centre. This 
can be considered as a drawback of our study. 
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SUMMARY  
 
 A haemodynamic stress response is associated with laryngoscopy 
and tracheal intubation almost all the time.  This would not cause much 
harm to most of the patients, but can increase morbidity in patients with 
coronary arterial disease, systemic hypertension, pre eclampsia, increased 
intra ocular pressure and cerebrovascular pathologies such as tumors, 
aneurysms or increased intracranial pressure. 
 
 Several techniques have been proposed to prevent or attenuate the 
haemodynamic responses following laryngoscopy and intubation, such as 
deepening of anaesthesia, omitting anticholinergic premedication, 
pretreatment with vasodilators such as nitroglycerin, beta-blockers, calcium 
channel blockers and opioids.  The recent studies aiming at controlling or 
attenuating the haemodynamic response to intubation and laryngoscopy 
focused on the effect of lornoxicam at different dosing regimens. 
  
 Lornoxicam is a relatively new drug, which was introduced as 
analgesic and antinflammatory.  The drug is well tolerated with limited side 
effects as compared with other NSAIDS.  Lornoxicam has been used in 
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randomized controlled trials to treat acute postoperative pain and to reduce 
the postoperative opioid requirements. 
 
 The present study was designed as a single-blind randomized 
controlled trial to investigate the effect of lornoxicam on the changes in 
blood pressure and heart rate (HR) observed during laryngoscopy and 
tracheal intubation in 50 ASA I & II patients.  They were divided into two 
groups of 25 each, one being the study group receiving 16 mg iv 
lornoxicam and the other the control group receiving iv placebo.  Heart rate 
and blood pressure were recorded at various intervals during laryngoscopy 
and endotracheal intubation.  It was observed that there was a statistically 
significant attenuation in heart rate and blood pressure response to 
laryngoscopy and intubation for the lornoxicam group.  Hence we can 
conclude that iv lornoxicam 16 mg 30 minutes before surgery is a simple 
and practical method for the attenuation of the stress response to 
laryngoscopy and endotracheal intubation. 
. 
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                                   CONCLUSION 
 
         From this study we conclude that intravenous lornoxicam 16mg  
given half an hour before surgical procedure significantly reduces 
haemodynamic responses to laryngoscopy and intubation.  
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EFFECT OF INTRAVENOUS LORNOXICAM ON THE HAEMODYNAMIC  
RESPONSE FOLLOWING LARYNGOSCOPY AND INTUBATION 
 
 CONTROL GROUP/TEST GROUP 
 
 NAME:                                            AGE/SEX:                      IPNO: 
   
WT:                                                HT:                       DATE OF SURGERY: 
 
DIAGNOSIS:                                             PROCEDURE: 
 
ASA GRADE:                                             MPG: 
                                    
                                     INVESTIGATIONS 
 
  HB:                            BT:                                 CT: 
 
  RFT:                            LFT:                               RBS: 
 
  CXR:                                          ECG: 
 
DURATION OF LARYNGOSCOPY: 
 
RELEVANT MEDICAL SURGICAL HISTORY: 
 
                               PARAMETERS MONITORED 
                  
                     
TIME HEART 
RATE 
SYSTOLIC 
BP 
DIASTOLIC 
BP 
MAP 
PRE 
LARYNGOSCOPY 
    
      1mt     
       3mt     
       5mt     
       10mt     
 
 
COMPLICATIONS: 
 
   URINE OUTPUT:
DIASTOLIC BLOOD PRESSURE LORNOXICAM GROUP in mm of Hg 
SLNO: IP NO        PRE 
LARYNGOSCOPY 
1 mt 3mt 5mt 10mt 
1. 1403494 68 75 66 65 66 
2. 1403526 64 68 60 58 60 
3. 1403314 64 70 62 60 60 
4. 1403146 72 78 70 68 68 
5. 1402840 68 74 66 64 64 
6. 1398343 74 80 72 70 72 
7. 1410943 76 82 70 72 70 
8. 1410827 74 80 72 70 70 
9. 1410865 68 72 66 64 66 
10. 1408038 64 64 62 60 60 
11. 1408674 70 76 68 66 64 
12. 1402830 70  74 68 66 66 
13. 1402840 64 70 62 60 60 
14. 1410478 78 80 76 74 74 
15. 1402946 76 82 84 72 72 
16. 1410753 74 80 72 70 72 
17. 1410762 70 72 68 66 64 
18. 1399542 68 68 66 64 66 
19. 141O883 60 62 58 58 60 
20. 1410911 62 68 60 60 62 
21. 141O734 64 70 62 60 60 
22. 1398842 70 76 68 66 64 
23. 1408657 62 68 60 60 62 
24. 1409871 62 64 60 60 62 
25. 1408649 60 60 58 58 60 
  68.08 72.52 66.24 64.44 64.96 
 
 
 
 
 SYSTOLIC BLOOD PRESSURE  LORNOXICAM GROUP  In  mm of Hg 
SLNO: IP NUMBER          PRE 
LARYNGOSCOPY 
       1 mt 3mt       5mt      10mt 
1. 1403494 116 120 118 126 120 
2. 1403526 110 128 120 120 110 
 3. 1403314 80 100 96 90 90 
 4. 1403146 100 130 116 116 120 
5.  1402840 110 148 106 100 100 
6. 1398343 122 130 132 110 110 
7. 1410943 98 110 100 108 110 
8. 1410827 104 110 100 108 100 
9. 1410865 128 140 132 126 126 
10. 1408038 98 100 104 100 100 
11. 1408674 100 116 112 112 112 
12. 1402830 130 138 128 126 126 
13. 1402840 124 128 126 120 128 
14. 1410478 114 120 110 116 110 
15. 1402946 134 130 128 128 126 
16. 1410753 120 140 132 124 124 
17. 1410762 100 110 112 110 104 
18. 1399542 108 106 108 110 110 
19. 141O883 112 114 112 110 110 
20. 1410911 110 124 116 110 112 
21. 141O734 96 100 112 100 100 
22. 1398842 112 120 110 112 110 
23. 1408657 130 136 130 132 132 
24. 1409871 128 132 126 122 122 
25. 1408649 108 130 124 124 116 
  112.48 121.6 116 114.16 113.12 
 
               SYSTOLIC BP PLACEBO GROUP in mm of Hg 
SL NO: IP NO: PRE 
LARYNGOSCOPY 
1mt   3mt    5mt    10mt 
1. 1395638 130 150 146 132 124 
2. 1393608 124 140 128 120 120 
3. 1396362 110 134 126 100 108 
4. 1400079 100 128 120 116 116 
5. 1400413 120 130 116 108 108 
6. 1400674 130 144 132 120 120 
7. 1403106 98 126 112 100 100 
8. 1402830 96 130 126 110 110 
9. 1406364 126 150 130 126 120 
10. 1403106 112 132 116 110 110 
11. 1393052 124 134 120 120 130 
12. 1393289 112 132 126 110 114 
13. 1393147 120 138 130 116 116 
14. 1403718 100 124 116 102 112 
15. 1403687 108 116 108 100 100 
16. 1407753 126 140 132 122 120 
17. 1401753 116 132 120 120 120 
18. 1406862 100 130 122 112 110 
19. 1406771 124 142 130 120 116 
20. 1416236 104 128 108 110 100 
21. 1410928 106 134 120 104 108 
22. 1410091 124 146 126 120 120 
23. 1408212 112 148 140 134 126 
24. 1407355 120 150 128 126 120 
25. 1410973 106 140 120 120 118 
  113.92 135.92 127.92 115.12 114.64 
 
                         DEMOGRAPHIC DATA LORNOXICAM GROUP 
SLNO: IPNO: AGE SEX Wt in kg Ht in cm ASA GRADE DURATION OF  
LARYNGOSCOPY 
IN SECONDS 
1. 1403494 36 M 61 175 ASA II 16 
2. 1403526 30 F 50 149 ASA II 15 
3. 1403314 37 M 64 170 ASA II 18 
4. 1403146 29 M 63 176 ASA II 14 
5. 1402840 24 F 54 158 ASA I 17 
6. 1398343 43 M 70 174 ASA II 14 
7. 1410943 23 M 68 171 ASA I 18 
8. 1410827 45 F 52 158 ASA II 16 
9. 1410865 40 M 68 173 ASA I 13 
10. 1408038 25 F 51 166 ASA II 13 
11. 1408674 35 F 47 164 ASA II 14 
12. 1402830 30 M 64 179 ASA I  12 
13. 1402840 22 F 48 160 ASA II 19 
14. 1410478 44 M 69 176 ASA I 15 
15. 1402946 38 F 46 165 ASA I 18 
16. 1410753 26 M 61 178 ASA II 17 
17. 1410762 39 F 50 163 ASA I  15 
18. 1399542 27 M 69 177 ASA II 16 
19. 141O883 38 F 58 157 ASA I  14 
20. 1410911 21 M 63 178 ASA II 16 
21. 141O734 41 F 53 162 ASA II 13 
22. 1398842 23 M 61 172 ASA I    17 
23. 1408657 43 F 52 161 ASA I  16 
24. 1409871 19 F 64 158 ASA II 18 
25. 1408649 25 F 65 160 ASA I 13 
  32.16+/-
4.3 
12/13 58.9+/-
5.4 
167.2+/-4.5 12/13 15.48 (1.1) 
                                 DEMOGRAPHIC DATA PLACEBO GROUP 
SLNO: IPNO: AGE SEX Wt in kg Ht in cm ASA GRADE DURATION OF  
LARYNGOSCOPY 
IN SECONDS 
1. 1395638 41 F 64 163 ASA II 12 
2. 1393608 34 F 51 160 ASA I 17 
3. 1396362 36 M 48 172 ASA II 13 
4. 1400079 22 F 68 156 ASA I 15 
5. 1400413 21 M 69 168 ASA II 14 
6. 1400674 33 M 70 154 ASA II 16 
7. 1403106 27 F 52 162 ASA II 18 
8. 1402830 38 M 61 173 ASA II 13 
9. 1406364 35 F 57 163 ASAII 13 
10. 1403106 44 M 70 177 ASA II 19 
11. 1393052 39 F 55 163 ASA I 15 
12. 1393289 21 F 50 162 ASA II 12 
13. 1393147 23 F 48 162 ASA II 10 
14. 1403718 27 M 62 180 ASA I 11 
15. 1403687 31 F 52 148 ASA II 17 
16. 1407753 19 M 64 173 ASA II 13 
17. 1401753 35 M 58 178 ASA I 15 
18. 1406862 40 F 51 157 ASA II 18 
19. 1406771 31 F 49 150 ASA I 13 
20. 1416236 26 F 52 155 ASA II 15 
21. 1410928 26 M 65 180 ASA II 14 
22. 1410091 43 F 54 152 ASA II 12 
23. 1408212 38 M 68 177 ASA II 17 
24. 1407355 29 F 53 158 ASA I 16 
25. 1410973 19 F 52 160 ASA II 14 
  31.12+/-
5.1 
10/15 57.72+/-
4.1 
166.44+/-
6.4 
11/14 14.5(1.7) 
DIASTOLIC BP PLACEBO GROUP im mm of Hg 
SL NO: IP NO;        PRE 
LARYNGOSCOPY 
    1mt     3mt     5mt   10mt 
1. 1395638 72 80 74 68 70 
2. 1393608 70 88 80 72 74 
3. 1396362 76 82 72 66 88 
4. 1400079 64 76 78 70 66 
5. 1400413 76 82 74 66 68 
6. 1400674 68 72 60 60 62 
7. 1403106 60 78 70 64 66 
8. 1402830 72 80 72 70 62 
9. 1406364 76 94 88 80 82 
10. 1403106 68 74 74 68 66 
11. 1393052 70 78 74 68 68 
12. 1393289 68 78 64 60 60 
13. 1393147 62 66 72 66 64 
14. 1403718 60 80 74 72 64 
15. 1403687 64 74 76 72 68 
16. 1407753 62 82 76 70 72 
17. 1401753 70 88 76 70 70 
18. 1406862 72 80 76 70 70 
19. 1406771 74 80 74 68 70 
20. 1416236 70 92 96 86 82 
21. 1410928 84 94 88 80 80 
22. 1410091 66 72 68 60 60 
23. 1408212 72 98 90 84 82 
24. 1407355 72 94 88 80 80 
25. 1410973 62 74 76 76 64 
  69.2 81.44 76.4 70.64 70.32 
 
                         HEART RATE  PLACEBO GROUP  
SLNO: IP NO:       PRE 
LARYNGOSCOPY 
1mt 3mt 5mt 10mt 
1. 1395638 82 108 100 92 84 
2. 1393608 88 110 106 100 90 
3. 1396362 90 110 110 98 98 
4. 1400079 94 120 120 114 98 
5. 1400413 88 116 118 94 90 
6. 1400674 78 104 106 94 88 
7. 1403106 96 118 1110 92 90 
8. 1402830 72 98 100 96 90 
9. 1406364 72 98 100 96 90 
10. 1403106 96 120 126 110 108 
11. 1393052 80 114 113 96 92 
12. 1393289 84 116 115 96 92 
13. 1393147 80 114 115 98 92 
14. 1403718 82 110 110 103 90 
15. 1403687 80 114 113 100 88 
16. 1407753 84 112 114 104 88 
17. 1401753 86 113 112 100 88 
18. 1406862 82 118 120 110 80 
19. 1406771 94 108 98 96 96 
20. 1416236 92 116 118 104  104 
21 1410928 96 108 106 94 88 
22. 1410091 68 110 109 104 90 
23. 1408212 82 113 112 104 84 
24. 1407355 102 132 128 110 96 
25. 1410973 100 126 120 106 90 
  87.04 114.16 112.76 101.4 91.96 
 
                            HEART RATE LORNOXICAM GROUP 
SL NO: IP NO: PRE 
LARYNGOSCOPY 
1mt 3mt 5mt 10mt 
1. 1403494 80 82 80 72 72 
2. 1403526 80 100 92 80 80 
3. 1403314 112 120 120 96 96 
4. 1403146 92 104 90 88 80 
5. 1402840 96 96 92 90 90 
6. 1398343 88 90 90 86 86 
7. 1410943 100 114 118 88 90 
8. 1410827 92 104 90 90 90 
9. 1410865 88 100 104 100 96 
10. 1408038 76 78 74 72 72 
11. 1408674 100 110 92 90 90 
12. 1402830 84 98 80 80 80 
13. 1402840 86 100 84 80 82 
14. 1410478 90 92 90 84 86 
15. 1402946 78 72 74 74 74 
16. 1410753 86 98 84 80 82 
17. 1410762 116 128 104 92 100 
18. 1399542 92 90 88 88 88 
19. 141O883 80 82 80 76 76 
20. 1410911 88 90 90 86 86 
21. 141O734 80 96 92 80 80 
22. 1398842 92 100 96 88 88 
23. 1408657 72 78 70 68 68 
24. 1409871 82 86 80 80 82 
25. 1408649 88 88 86 86 86 
  88.72 95.84 89.6 83.76 84 
 
                              MEAN ARTERIAL PRESSURE CONTROL GROUP in mm  of Hg 
SL NO: IP NO:       PRE 
LARYNGOSCOPY 
1mt   3mt     5mt   10mt 
1. 1395638 91.33333 103.3333 98 89.33333 88 
2. 1393608 88 105.3333 96 88 89.33333 
3. 1396362 87.33333 99.33333 90 77.33333 94.66667 
4. 1400079 76 93.33333 92 85.33333 82.66667 
5. 1400413 90.66667 98 88 80 81.33333 
6. 1400674 88.66667 96 84 80 81.33333 
7. 1403106 72.66667 94 84 76 77.33333 
8. 1402830 80 96.66667 90 83.33333 78 
9. 1406364 92.66667 112.6667 102 95.33333 94.66667 
10. 1403106 82.66667 93.33333 88 82 80.66667 
11. 1393052 88 96.66667 89.33333 85.33333 88.66667 
12. 1393289 82.66667 96 118 76.66667 78 
13. 1393147 81.33333 90 91.33333 82.66667 81.33333 
14. 1403718 73.33333 94.66667 88 82 80 
15. 1403687 78.66667 88 86.66667 81.33333 78.66667 
16. 1407753 83.33333 101.3333 94.66667 87.33333 88 
17. 1401753 85.33333 102.6667 90.66667 86.66667 86.66667 
18. 1406862 81.33333 96.66667 91.33333 84 83.33333 
19. 1406771 90.66667 100.6667 92.66667 85.33333 85.33333 
20. 1416236 81.33333 104 100 94 88 
21. 1410928 91.33333 107.3333 98.66667 88 89.33333 
22. 1410091 85.33333 96.66667 87.33333 80 80 
23. 1408212 85.33333 114.6667 106.6667 100.6667 96.66667 
24. 1407355 88 112.6667 101.3333 95.33333 93.33333 
25. 1410973 776.66667 96 90.66667 90.66667 82 
  84.1 99.75 93.57 85.47 85.09 
 
    MEAN ARTERIAL PRESSURE LORNOXICAM GROUP In mm of Hg 
 
 
 
SLNO: IP 
NUMBER 
PRELARYNGOSCOPY 1MT 3MT 5MT 10MT 
1. 1403494 84 90 83.33333 85.33333 84 
2. 1403526 79.33333 88 80 78.66667 76.66667 
3. 1403314 69.33333 80 73.33333 70 70 
4. 1403146 88 95.33333333 85.33333 84 85.33333 
5. 1402840 82 92 79.33333 76 76 
6. 1398343 90 96.66666667 92 83.33333 84.66667 
7. 1410943 83.33333 91.33333333 80 84 83.33333 
8. 1410827 84 90 81.33333 80.66667 80 
9. 1410865 88 94.66666667 88 84.66667 86 
10. 1408038 75.33333 76 76 73.33333 73.33333 
11. 1408674 80 89.33333333 82.66667 81.33333 80 
12. 1402830 90 95.33333333 88 86 86 
13. 1402840 84 89.33333333 83.33333 80 82.66667 
14. 1410478 90 93.33333333 87.33333 88 86 
15. 1402946 95.33333 98 98.66667 90.66667 90 
16. 1410753 89.33333 100 92 88 89.33333 
17. 1410762 80 84.66666667 82.66667 80.66667 77.33333 
18 1399542 81.33333 80.66666667 80 79.33333 80.66667 
19. 141O883 77.33333 79.33333333 76 75.33333 76.66667 
20. 1410911 78 86.66666667 78.66667 76.66667 78.66667 
21. 141O734 74.66667 80 75.33333 73.33333 73.33333 
22. 1398842 84 90.66666667 82 81.33333 79.33333 
23. 1408657 84.66667 90.66666667 83.33333 84 85.33333 
24. 1409871 84 86.66666667 82 80.66667 82 
25. 1408649 76 83.33333333 80 80 78.66667 
  82.88 88.88 82.82 81.01 81.01 
 
